Abdel-Wahab Wessam M, Moussa Farouzia I, Saad Najwa A
Department of Biology, College of Medicine, University of Dammam, Dammam, Saudi Arabia; Department of Zoology, Faculty of Science, University of Alexandria, Alexandria, Egypt.
Department of Zoology, Faculty of Science, University of Alexandria, Alexandria, Egypt.
Drug Des Devel Ther. 2017 Mar 20;11:901-908. doi: 10.2147/DDDT.S131316. eCollection 2017.
Cisplatin (cis-diaminedichloroplatinum II; CDDP) is an effective anticancer drug, but it has limitations because of its nephrotoxicity. This study investigates the protective effect of -acetylcysteine (NAC) and taurine (TAU), both individually and in combination, against CDDP nephrotoxicity in rats. For this purpose, 48 male rats were assigned into eight groups (n=6) as follows: 1) control group, 2) NAC group, 3) TAU group, 4) NAC-TAU group, 5) CDDP group, 6) CDDP-NAC group, 7) CDDP-TAU group, and 8) CDDP-NAC-TAU group. Cisplatin was administered as a single intraperitoneal injection at a concentration of 6 mg/kg. Three days after CDDP administration, NAC (50 mg/kg) and/or TAU (50 mg/kg) were administered three times weekly for four consecutive weeks. Kidney function markers in serum, urinary glucose and protein, as well as oxidant and antioxidant parameters in renal tissue were assessed. Administration of CDDP significantly elevated urinary glucose and protein, as well as serum creatinine, urea, and uric acid. Moreover, CDDP enhanced lipid peroxidation and suppressed the major enzymatic antioxidants in the kidney tissue. Treatment with NAC or TAU protected against the alterations in the serum, urine, and renal tissue when used individually along with CDDP. Furthermore, a combined therapy of both was more effective in ameliorating CDDP-induced nephrotoxicity, which points out to their synergistic effect.
顺铂（顺二氯二氨铂II；CDDP）是一种有效的抗癌药物，但因其肾毒性而存在局限性。本研究调查了N - 乙酰半胱氨酸（NAC）和牛磺酸（TAU）单独及联合使用对大鼠顺铂肾毒性的保护作用。为此，将48只雄性大鼠分为八组（n = 6），如下：1）对照组，2）NAC组，3）TAU组，4）NAC - TAU组，5）CDDP组，6）CDDP - NAC组，7）CDDP - TAU组，8）CDDP - NAC - TAU组。顺铂以6 mg/kg的浓度单次腹腔注射给药。顺铂给药三天后，NAC（50 mg/kg）和/或TAU（50 mg/kg）每周给药三次，连续给药四周。评估血清中的肾功能标志物、尿糖和尿蛋白，以及肾组织中的氧化和抗氧化参数。给予顺铂显著升高了尿糖、尿蛋白以及血清肌酐、尿素和尿酸。此外，顺铂增强了脂质过氧化并抑制了肾组织中的主要酶抗氧化剂。单独与顺铂一起使用时，NAC或TAU治疗可防止血清、尿液和肾组织的改变。此外，两者的联合治疗在改善顺铂诱导的肾毒性方面更有效，这表明它们具有协同作用。
